Going for broke: Targeting the human cancer pseudokinome

Biochemical Journal

Volumn 465, Issue , 2015, Pages 195-211

  Bailey, Fiona P ^a   Byrne, Dominic P ^a   McSkimming, Daniel ^b   Kannan, Natarajan ^b   Eyers, Patrick A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Cancer; Kinase; Mutation; Pseudokinase; Pseudokinome; Signalling

Indexed keywords

AMINO ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 3; JANUS KINASE; LIGAND; MIXED LINEAGE KINASE; ONCOPROTEIN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PSEUDOKINOME; RAS 1 PROTEIN; RAS 2 PROTEIN; RAS PROTEIN; STRAD ALPHA PROTEIN; UNCLASSIFIED DRUG; WITH NO LYSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEOME; PYRAZOLE DERIVATIVE; RUXOLITINIB; TUMOR PROTEIN;

ARTICLE; DRUG TARGETING; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PROTEIN STRUCTURE; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DRUG DELIVERY SYSTEM; ENZYMOLOGY; GENE LOCUS; GENETICS; METABOLISM; NEOPLASMS; PROCEDURES;

VERTEBRATA;

DRUG DELIVERY SYSTEMS; GENETIC LOCI; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOME; PYRAZOLES;

EID: 84920568398     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20141060     Document Type: Article

References (151)

1. Kannan, N., and Taylor., S. S., Zhai, Y., Venter, J. C. and Manning, G. (2007) Structural and functional diversity of the microbial kinome. PLoS Biol. 5, e17
2. Manning, G., and Whyte., D. B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934
3. Caenepeel, S., Charydczak, G., Sudarsanam, S., Hunter, T. and Manning, G. (2004) The mouse kinome: discovery and comparative genomics of all mouse protein kinases. Proc. Natl. Acad. Sci. U.S.A. 101, 11707-11712
4. Manning, G., and Reiner., D. S., Lauwaet, T., Dacre, M., Smith, A., Zhai, Y., Svard, S. and Gillin, F. D. (2011) The minimal kinome of Giardia lambliailluminates early kinase evolution and unique parasite biology. Genome Biol. 12, R66
5. Talevich, E. and Kannan, N. (2013) Structural and evolutionary adaptation of rhoptry kinases and pseudokinases, a family of coccidian virulence factors. BMC Evol. Biol. 13, 117
6. Eyers, P. A. and Murphy, J. M. (2013) Dawn of the dead: protein pseudokinases signal new adventures in cell biology. Biochem. Soc. Trans. 41, 969-974
7. Scheeff, E. D., Eswaran, J., Bunkoczi, G., Knapp, S. and Manning, G. (2009) Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17, 128-138
8. Boudeau, J., Miranda-Saavedra, D., Barton, G. J. and Alessi, D. R. (2006) Emerging roles of pseudokinases. Trends Cell Biol. 16, 443-452
9. Murphy, J. M., Zhang, Q., Young, S. N., Reese, M. L., Bailey, F. P., Eyers, P. A., Ungureanu, D., Hammaren, H., Silvennoinen, O., Varghese, L. N. et al. (2014) A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem. J. 457, 323-334
10. Hu, J., Yu, H., Kornev, A. P., Zhao, J., Filbert, E. L., Taylor, S. S. and Shaw, A. S. (2011) Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl. Acad. Sci. U.S.A. 108, 6067-6072
11. Silvennoinen, O., Ungureanu, D., Niranjan, Y., Hammaren, H., Bandaranayake, R. and Hubbard, S. R. (2013) New insights into the structure and function of the pseudokinase domain in JAK2. Biochem. Soc. Trans. 41, 1002-1007
12. Zeqiraj, E., and Filippi., B. M., Goldie, S., Navratilova, I., Boudeau, J., Deak, M., Alessi, D. R. and van Aalten, D. M. (2009) ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor. PLoS Biol. 7, e1000126
13. Murphy, J. M., and Czabotar., P. E., Hildebrand, J. M., Lucet, I. S., Zhang, J. G., Alvarez-Diaz, S., Lewis, R., Lalaoui, N., Metcalf, D., Webb, A. I. et al. (2013) The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443-453
14. Reiterer, V., Eyers, P. A. and Farhan, H. (2014) Day of the dead: pseudokinases and pseudophosphatases in physiology and disease. Trends Cell Biol. 24, 489-505
15. Barouch-Bentov, R., Che, J., and Lee., C. C., Yang, Y., Herman, A., Jia, Y., Velentza, A., Watson, J., Sternberg, L., Kim, S. et al. (2009) A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol. Cell 33, 43-52
16. Taylor, S. S. and Kornev, A. P. (2011) Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci. 36, 65-77
17. Suijkerbuijk, S. J., van Dam, T. J., Karagoz, G. E., von Castelmur, E., Hubner, N. C., Duarte, A. M., Vleugel, M., Perrakis, A., Rudiger, S. G., Snel, B. et al. (2012) The vertebrate mitotic checkpoint protein BUBR1 is an unusual pseudokinase. Dev. Cell 22, 1321-1329
18. Higgins, J. M. (2001) Haspin-like proteins: a new family of evolutionarily conserved putative eukaryotic protein kinases. Protein Sci. 10, 1677-1684
19. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275-282
20. Shi, F. M., and Telesco., S. E., Liu, Y. T., Radhakrishnan, R. and Lemmon, M. A. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. U.S.A. 107, 7692-7697
21. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C.-F., Neubert, T. A., Skoda, R. C., Hubbard, S. R. et al. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971-U921
22. 2+ -independent neurexin kinase. Cell 133, 328-339
23. Yoshida-Moriguchi, T., Willer, T., and Anderson., M. E., Venzke, D., Whyte, T., Muntoni, F., Lee, H., Nelson, S. F., Yu, L. and Campbell, K. P. (2013) SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 341, 896-899
24. Becher, I., and Savitski., M. M., Savitski, M. F., Hopf, C., Bantscheff, M. and Drewes, G. (2013) Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP. ACS Chem. Biol. 8, 599-607
25. Fedorov, O., Muller, S. and Knapp, S. (2010) The (un)targeted cancer kinome. Nat. Chem. Biol. 6, 166-169
26. Knapp, S., Arruda, P., Blagg, J., Burley, S., and Drewry., D. H., Edwards, A., Fabbro, D., Gillespie, P., and Gray., N. S., Kuster, B. et al. (2013) A public-private partnership to unlock the untargeted kinome. Nat. Chem. Biol. 9, 3-6
27. Mendrola, J. M., Shi, F., Park, J. H. and Lemmon, M. A. (2013) Receptor tyrosine kinases with intracellular pseudokinase domains. Biochem. Soc. Trans. 41, 1029-1036
28. Zeqiraj, E. and van Aalten, D. M. (2010) Pseudokinases-remnants of evolution or key allosteric regulators? Curr. Opin. Struct. Biol. 20, 772-781
29. Jura, N., Shan, Y., Cao, X., Shaw, D. E. and Kuriyan, J. (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. U.S.A. 106, 21608-21613
30. Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X. and Stern, H. M. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878-5887
31. Holbro, T., and Beerli., R. R., Maurer, F., Koziczak, M., Barbas, 3rd, C. F. and Hynes, N. E. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 100, 8933-8938
32. Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z., and Thomas., R. K., Greulich, H., Schinzel, A. et al. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17, 298-310
33. Mills, G. B. and Yarden, Y. (2010) The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. Cancer Cell 17, 217-218
34. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J. et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043
35. Huang, S., Li, C., Armstrong, E. A., Peet, C. R., Saker, J., Amler, L. C., Sliwkowski, M. X. and Harari, P. M. (2013) Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73, 824-833
36. Davis, M. I., and Hunt., J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K. and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-51
37. Steinbach, A., Clark, S. M. and Clemmons, A. B. (2013) Bosutinib: a novel src/abl kinase inhibitor for chronic myelogenous leukemia. J. Adv. Pract. Oncol. 4, 451-455
38. Cortes, J. E., and Kim., D. W., Kantarjian, H. M., Brummendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M. et al. (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J. Clin. Oncol. 30, 3486-3492
39. Littlefield, P., Moasser, Mark, M. and Jura, N. (2014) An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem. Biol. 21, 453-458
40. Claus, J., Cameron, A. J. and Parker, P. J. (2013) Pseudokinase drug intervention: a potentially poisoned chalice. Biochem. Soc. Transact. 41, 1083-1088
41. The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337
42. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397
43. James, C., Ugo, V., Le Couedic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148
44. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M. and Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790
45. Baxter, E. J., and Scott., L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061
46. Babon, J. J., and Lucet., I. S., Murphy, J. M., Nicola, N. A. and Varghese, L. N. (2014) The molecular regulation of Janus kinase (JAK) activation. Biochem. J. 462, 1-13
47. Saharinen, P., Takaluoma, K. and Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395
48. Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468
49. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., and Saunders., L. M., Mullally, A., Abdel-Wahab, O. et al. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155-159
50. Brooks, A. J., Dai, W., O'Mara, M. L., Abankwa, D., Chhabra, Y., Pelekanos, R. A., Gardon, O., Tunny, K. A., Blucher, K. M., Morton, C. J. et al. (2014) Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344, 1249783
51. Shan, Y., Gnanasambandan, K., Ungureanu, D., Kim, E. T., Hammaren, H., Yamashita, K., Silvennoinen, O., Shaw, D. E. and Hubbard, S. R. (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat. Struct. Mol. Biol. 21, 579-584
52. Hart, S., and Goh., K. C., Novotny-Diermayr, V., Hu, C. Y., Hentze, H., and Tan., Y. C., Madan, B., Amalini, C., Loh, Y. K., Ong, L. C. et al. (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25, 1751-1759
53. Kantarjian, H. M., and Silver., R. T., Komrokji, R. S., Mesa, R. A., Tacke, R. and Harrison, C. N. (2013) Ruxolitinib for myelofibrosis-an update of its clinical effects. Clin. Lymphoma Myeloma Leuk. 13, 638-645
54. Ma, L., and Clayton., J. R., Walgren, R. A., Zhao, B., Evans, R. J., Smith, M. C., Heinz-Taheny, K. M., Kreklau, E. L., Bloem, L., Pitou, C. et al. (2013) Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 3, e109
55. LaFave, L. M. and Levine, R. L. (2012) JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol. Sci. 33, 574-582
56. Xu, B. E., Min, X., Stippec, S., Lee, B. H., Goldsmith, E. J. and Cobb, M. H. (2002) Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J. Biol. Chem. 277, 48456-48462
57. Min, X., and Lee., B. H., Cobb, M. H. and Goldsmith, E. J. (2004) Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 12, 1303-1311
58. Xu, B., and English., J. M., Wilsbacher, J. L., Stippec, S., Goldsmith, E. J. and Cobb, M. H. (2000) WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J. Biol. Chem. 275, 16795-16801
59. Lenertz, L. Y., and Lee., B. H., Min, X. S., Xu, B. E., Wedin, K., Earnest, S., Goldsmith, E. J. and Cobb, M. H. (2005) Properties of WNK1 and implications for other family members. J. Biol. Chem. 280, 26653-26658
60. Piala, A. T., and Moon., T. M., Akella, R., He, H., Cobb, M. H. and Goldsmith, E. J. (2014) Chloride sensing by WNK1 involves inhibition of autophosphorylation. Sci. Signal. 7, ra41
61. Xu, B. E., and English., J. M., Wilsbacher, J. L., Stippec, S., Goldsmith, E. J. and Cobb, M. H. (2000) WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J. Biol. Chem. 275, 16795-16801
62. Verissimo, F. and Jordan, P. (2001) WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 20, 5562-5569
63. - cotransporter in HeLa cells. Proc. Natl. Acad. Sci. U.S.A. 103, 10883-10888
64. Alessi, D. R., Zhang, J., Khanna, A., Hochdorfer, T., Shang, Y. and Kahle, K. T. (2014) The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters. Sci. Signal. 7, re3
65. - cotransporter facilitates glioma migration. Mol. Cancer 13, 31
66. Lizcano, J. M., Goransson, O., Toth, R., Deak, M., and Morrice., N. A., Boudeau, J., Hawley, S. A., Udd, L., Makela, T. P., Hardie, D. G. et al. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23, 833-843
67. Zeqiraj, E., and Filippi., B. M., Deak, M., Alessi, D. R. and van Aalten, D. M. F. (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326, 1707-1711
68. Jishage, K., Nezu, J., Kawase, Y., Iwata, T., Watanabe, M., Miyoshi, A., Ose, A., Habu, K., Kake, T., Kamada, N. et al. (2002) Role of Lkb1, the causative gene of Peutz-Jeghers syndrome, in embryogenesis and polyposis. Proc. Natl. Acad. Sci. U.S.A. 99, 8903-8908
69. Murphy, J. M., and Lucet., I. S., Hildebrand, J. M., Tanzer, M. C., Young, S. N., Sharma, P., Lessene, G., Alexander, W. S., Babon, J. J., Silke, J. et al. (2014) Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. Biochem. J. 457, 369-377
70. Hildebrand, J. M., and Tanzer., M. C., Lucet, I. S., Young, S. N., Spall, S. K., Sharma, P., Pierotti, C., Garnier, J. M., Dobson, R. C., Webb, A. I. et al. (2014) Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 111, 15072-15077
71. Sun, L. M., and Wang., H. Y., Wang, Z. G., He, S. D., Chen, S., Liao, D. H., Wang, L., Yan, J. C., Liu, W. L., Lei, X. G. et al. (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213-227
72. Forbes, S. A., Bhamra, G., Bamford, S., Dawson, E., Kok, C., Clements, J., Menzies, A., and Teague., J. W., Futreal, P. A. and Stratton, M. R. (2008) The catalogue of somatic mutations in cancer (COSMIC). Curr. Protoc. Hum. Genet., Chapter 10, Unit 10.11
73. Shaw, A. S., and Kornev., A. P., Hu, J., Ahuja, L. G. and Taylor, S. S. (2014) Kinases and pseudokinases: lessons from RAF. Mol. Cell. Biol. 34, 1538-1546
74. Zhang, H., and Koo., C. Y., Stebbing, J. and Giamas, G. (2013) The dual function of KSR1: a pseudokinase and beyond. Biochem. Soc. Trans. 41, 1078-1082
75. Muller, J., Ory, S., Copeland, T., Piwnica-Worms, H. and Morrison, D. K. (2001) C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol. Cell 8, 983-993
76. Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D. and Therrien, M. (2002) KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev. 16, 427-438
77. Xing, H., Kornfeld, K. and Muslin, A. J. (1997) The protein kinase KSR interacts with 14-3-3 protein and Raf. Curr. Biol. 7, 294-300
78. Brennan, D. F., and Dar., A. C., Hertz, N. T., Chao, W. C., Burlingame, A. L., Shokat, K. M. and Barford, D. (2011) A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366-369
79. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435
80. Xing, H. R. and Kolesnick, R. (2001) Kinase suppressor of Ras signals through Thr269 of c-Raf-1. J. Biol. Chem. 276, 9733-9741
81. Zafrullah, M., Yin, X., Haimovitz-Friedman, A., Fuks, Z. and Kolesnick, R. (2009) Kinase suppressor of Ras transphosphorylates c-Raf-1. Biochem. Biophys. Res. Commun. 390, 434-440
82. Yan, F., and John., S. K., Wilson, G., Jones, D. S., Washington, M. K. and Polk, D. B. (2004) Kinase suppressor of Ras-1 protects intestinal epithelium from cytokine-mediated apoptosis during inflammation. J. Clin. Invest. 114, 1272-1280
83. Yan, F. and Polk, D. B. (2001) Kinase suppressor of ras is necessary for tumor necrosis factor alpha activation of extracellular signal-regulated kinase/mitogen-activated protein kinase in intestinal epithelial cells. Cancer Res. 61, 963-969
84. Xing, H. R., Cordon-Cardo, C., Deng, X., Tong, W., Campodonico, L., Fuks, Z. and Kolesnick, R. (2003) Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat. Med. 9, 1266-1268
85. Kortum, R. L. and Lewis, R. E. (2004) The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol. Cell. Biol. 24, 4407-4416
86. Fisher, K. W., Das, B., Kortum, R. L., Chaika, O. V. and Lewis, R. E. (2011) Kinase suppressor of ras 1 (KSR1) regulates PGC1alpha and estrogen-related receptor alpha to promote oncogenic Ras-dependent anchorage-independent growth. Mol. Cell. Biol. 31, 2453-2461
87. Fernandez, M. R., Henry, M. D. and Lewis, R. E. (2012) Kinase suppressor of Ras 2 (KSR2) regulates tumor cell transformation via AMPK. Mol. Cell. Biol. 32, 3718-3731
88. Masoner, V., Das, R., Pence, L., Anand, G., LaFerriere, H., Zars, T., Bouyain, S. and Dobens, L. L. (2013) The kinase domain of Drosophila Tribbles is required for turnover of fly C/EBP during cell migration. Dev. Biol. 375, 33-44
89. Rorth, P., Szabo, K. and Texido, G. (2000) The level of C/EBP protein is critical for cell migration during Drosophila oogenesis and is tightly controlled by regulated degradation. Mol. Cell 6, 23-30
90. Keeshan, K., Bailis, W., Dedhia, P. H., Vega, M. E., Shestova, O., Xu, L., Toscano, K., Uljon, S. N., Blacklow, S. C. and Pear, W. S. (2010) Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood 116, 4948-4957
91. Keeshan, K., and He., Y. P., Wouters, B. J., Shestova, O., Xu, L. W., Sai, H., Rodriguez, C. G., Maillard, I., Valk, P., Carroll, M. et al. (2006) Tribbles homolog 2 (Trib2) inactivates C/EBPalpha and causes acute myelogenous leukemia. Blood 108, 233a
92. Grandinetti, K. B., and Stevens., T. A., Ha, S., Salamone, R. J., Walker, J. R., Zhang, J., Agarwalla, S., Tenen, D. G., Peters, E. C. and Reddy, V. A. (2011) Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBP alpha. Oncogene 30, 3328-3335
93. Zanella, F., Renner, O., Garcia, B., Callejas, S., Dopazo, A., Peregrina, S., Carnero, A. and Link, W. (2010) Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene 29, 2973-2982
94. Wang, J., Park, J.-S., Wei, Y., Rajurkar, M., Cotton, J. L., Fan, Q., Lewis, B. C., Ji, H. and Mao, J. (2013) TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBP alpha function. Mol. Cell 51, 211-225
95. Jin, G., Yamazaki, Y., Takuwa, M., Takahara, T., Kaneko, K., Kuwata, T., Miyata, S. and Nakamura, T. (2007) Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 109, 3998-4005
96. Yokoyama, T., Kanno, Y., Yamazaki, Y., Takahara, T., Miyata, S. and Nakamura, T. (2010) Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood 116, 2768-2775
97. Yokoyama, T., Toki, T., Aoki, Y., Kanezaki, R., and Park., M. J., Kanno, Y., Takahara, T., Yamazaki, Y., Ito, E., Hayashi, Y. et al. (2012) Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. Blood 119, 2608-2611
98. Kitamoto, A., Kitamoto, T., Nakamura, T., Ogawa, Y., Yoneda, M., Hyogo, H., Ochi, H., Mizusawa, S., Ueno, T., Nakao, K. et al. (2014) Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr. J. 61, 683-689
99. Dedhia, P. H., Keeshan, K., Uljon, S., Xu, L. W., Vega, M. E., Shestova, O., Zaks-Zilberman, M., Romany, C., Blacklow, S. C. and Pear, W. S. (2010) Differential ability of Tribbles family members to promote degradation of C/EBP alpha and induce acute myelogenous leukemia. Blood 116, 1321-1328
100. Miyoshi, N., Ishii, H., Mimori, K., Takatsuno, Y., Kim, H., Hirose, H., Sekimoto, M., Doki, Y. and Mori, M. (2009) Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis. Br. J. Cancer 101, 1664-1670
101. Izrailit, J., and Berman., H. K., Datti, A., Wrana, J. L. and Reedijk, M. (2013) High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFbeta pathways as fundamental Notch regulators in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 1714-1719
102. Wennemers, M., Bussink, J., Scheijen, B., Nagtegaal, I. D., van Laarhoven, H. W., Raleigh, J. A., Varia, M. A., Heuvel, J. J., Rouschop, K. M., Sweep, F. C. et al. (2011) Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Res. 13, R82
103. Zhang, W., Liu, J., Tian, L., Liu, Q., Fu, Y. and Garvey, W. T. (2013) TRIB3 mediates glucose-induced insulin resistance via a mechanism that requires the hexosamine biosynthetic pathway. Diabetes 62, 4192-4200
104. Yu, H., He, K., Li, L., Sun, L., Tang, F., Li, R., Ning, W. and Jin, Y. (2013) Deletion of STK40 protein in mice causes respiratory failure and death at birth. J. Biol. Chem. 288, 5342-5352
105. Liu, L., and Yu., X. Z., Li, T. S., Song, L. X., Chen, P. L., Suo, T. L., Li, Y. H., Wang, S. D., Chen, Y., Ren, Y. M. et al. (2004) A novel protein tyrosine kinase NOK that shares homology with platelet-derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res. 64, 3491-3499
106. Chen, Y., and Li., Y. H., Chen, X. P., Gong, L. N., Zhang, S. P., Chang, Z. J., Zhang, X. F., Fu, X. Y. and Liu, L. (2005) Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res. 65, 10838-10846
107. Kondoh, T., Kobayashi, D., Tsuji, N., Kuribayashi, K. and Watanabe, N. (2009) Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia. Exp. Hematol. 37, 824-830
108. Amachika, T., Kobayashi, D., Moriai, R., Tsuji, N. and Watanabe, N. (2007) Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer 56, 337-340
109. Jackson, K. A., Oprea, G., Handy, J. and Kimbro, K. S. (2009) Aberrant STYK1 expression in ovarian cancer tissues and cell lines. J. Ovarian Res. 2, 15
110. Chung, S. Y., Tamura, K., Furihata, M., Uemura, M., Daigo, Y., Nasu, Y., Miki, T., Shuin, T., Fujioka, T., Nakamura, Y. et al. (2009) Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. Cancer Sci. 100, 2109-2114
111. Kimbro, K. S., Duschene, K., Willard, M., Moore, J.-A. and Freeman, S. (2008) A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol. Biol. Rep. 35, 23-27
112. Nirasawa, S., Kobayashi, D., Kondoh, T., Kuribayashi, K., Tanaka, M., Yanagihara, N. and Watanabe, N. (2014) Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia. Int. J. Oncol. 45, 1867-1874
113. Cohen, P. and Alessi, D. R. (2013) Kinase drug discovery - what's next in the field? ACS Chem. Biol. 8, 96-104
114. Dusa, A., Mouton, C., Pecquet, C., Herman, M. and Constantinescu, S. N. (2010) JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS ONE 5, e11157
115. Jaiswal, B. S., and Kljavin., N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A. et al. (2013) Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603-617
116. Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., and Boyle., F. T., Hewitt, N., Plant, H. and Hedge, P. (1999) Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568
117. Qin, J., Xie, P., Ventocilla, C., Zhou, G., Vultur, A., Chen, Q., Liu, Q., Herlyn, M., Winkler, J. and Marmorstein, R. (2012) Identification of a novel family of BRAF(V600E) inhibitors. J. Med. Chem. 55, 5220-5230
118. Cantwell-Dorris, E. R., O'Leary, J. J. and Sheils, O. M. (2011) BRAF(V600E): implications for carcinogenesis and molecular therapy. Mol. Cancer Therap. 10, 385-394
119. Dar, A. C., Dever, T. E. and Sicheri, F. (2005) Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 122, 887-900
120. Pellicena, P. and Kuriyan, J. (2006) Protein-protein interactions in the allosteric regulation of protein kinases. Curr. Opin. Struct. Biol. 16, 702-709
121. Vainchenker, W., Delhommeau, F., Constantinescu, S. N. and Bernard, O. A. (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118, 1723-1735
122. Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O. and Hubbard, S. R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759
123. Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R. and Eigenbrot, C. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U.S.A. 111, 8025-8030
124. Taylor, S. S., Shaw, A., Hu, J., Meharena, H. S. and Kornev, A. (2013) Pseudokinases from a structural perspective. Biochem. Soc. Trans. 41, 981-986
125. Labesse, G., Gelin, M., Bessin, Y., Lebrun, M., Papoin, J., Cerdan, R., Arold, S. T. and Dubremetz, J. F. (2009) ROP2 from Toxoplasma gondii: a virulence factor with a protein-kinase fold and no enzymatic activity. Structure 17, 139-146
126. Fukuda, K., Gupta, S., Chen, K., Wu, C. and Qin, J. (2009) The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. Mol. Cell 36, 819-830
127. Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Muller, S., Bullock, A. N., Schwaller, J., Sundstrom, M. and Knapp, S. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. U.S.A. 104, 20523-20528
128. Chu, M. L., Lang, Z., Chavas, L. M., Neres, J., Fedorova, O. S., Tabernero, L., Cherry, M., and Williams., D. H., Douglas, K. T. and Eyers, P. A. (2010) Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes. Biochemistry 49, 1689-1701
129. Fabbro, D., Cowan-Jacob, S. W., Mobitz, H. and Martiny-Baron, G. (2012) Targeting cancer with small-molecular-weight kinase inhibitors. Methods: Mol. Biol. 795, 1-34
130. Kufareva, I. and Abagyan, R. (2008) Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J. Med. Chem. 51, 7921-7932
131. 2+ -sensitive kinase. Sci. Signal. 3, ra33
132. Zhang, J., and Adrian., F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F. et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506
133. Cross, D. A., and Ashton., S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R., and Ward., R. A., Mellor, M. J. et al. (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046-1061
134. Schirmer, A., Kennedy, J., Murli, S., Reid, R. and Santi, D. V. (2006) Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc. Natl. Acad. Sci. U.S.A. 103, 4234-4239
135. Honigberg, L. A., and Smith., A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., and Thamm., D. H., Miller, R. A. et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U.S.A. 107, 13075-13080
136. Walter, A. O., and Sjin., R. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z. et al. (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3, 1404-1415
137. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., and Buhrlage., S. J., Jones, L. H. and Gray, N. S. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20, 146-159
138. Yun, C. H., and Mengwasser., K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M. and Eck, M. J. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 105, 2070-2075
139. Cortes, J. E., Talpaz, M. and Kantarjian, H. (2014) Ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 370, 577
140. Xie, T., and Lim., S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., and Tae., H. S., Riddle, S. M. et al. (2014) Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10, 1006-1012
141. Sammond, D. M., and Nailor., K. E., Veal, J. M., Nolte, R. T., Wang, L., Knick, V. B., Rudolph, S. K., Truesdale, A. T., and Nartey., E. N., Stafford, J. A. et al. (2005) Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorg. Med. Chem. Lett. 15, 3519-3523
142. Gosal, G., Kochut, K. J. and Kannan, N. (2011) Pro Kin O: an ontology for integrative analysis of protein kinases in cancer. PLoS ONE 6, e28782
143. Bayliss, R., Fry, A., Haq, T. and Yeoh, S. (2012) On the molecular mechanisms of mitotic kinase activation. Open Biol. 2, 120136
144. Mashalidis, E. H., Sledz, P., Lang, S. and Abell, C. (2013) A three-stage biophysical screening cascade for fragment-based drug discovery. Nat. Protoc. 8, 2309-2324
145. DeSantis, K., Reed, A., Rahhal, R. and Reinking, J. (2012) Use of differential scanning fluorimetry as a high-throughput assay to identify nuclear receptor ligands. Nucl. Recept. Signal. 10, e002
146. Lucet, I. S., Babon, J. J. and Murphy, J. M. (2013) Techniques to examine nucleotide binding by pseudokinases. Biochem. Soc. Trans. 41, 975-980
147. Niesen, F. H., Berglund, H. and Vedadi, M. (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212-2221
148. Krishna, S. N., and Luan., C. H., Mishra, R. K., Xu, L., Scheidt, K. A., Anderson, W. F. and Bergan, R. C. (2013) A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4. PLoS ONE 8, e81504
149. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., and Smith., W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I. et al. (2010) Selective inhibition of BET bromodomains. Nature 468, 1067-1073
150. Ciceri, P., Muller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C. et al. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 10, 305-312
151. Drewry, D. H., Willson, T. M. and Zuercher, W. J. (2014) Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS). Curr. Top. Med. Chem. 14, 340-342